Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry

Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry REVIEW ARTICLE Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry Hadi Yaziji, MD,* Clive R. Taylor, MA, MD, D.Phil,w Neal S. Goldstein, MD,z David J. Dabbs, MD,y Elizabeth H. Hammond, MD,J Bryan Hewlett, ART (CSMLS), MLT (CMLTO),z Alton D. Floyd, PhD,* Todd S. Barry, MD,# Alvn W. Martin, MD, ** Sunil Badve, MD, ww Frederick Baehner, MD, ww Richard W. Cartun, MD,zz Richard N. Eisen, MD,yy Paul E. Swanson, MD,JJ Stephen M. Hewitt, MD, PhD,zz Mogen Vyberg, MD,## and David G. Hicks, MD*** and Members of the Standardization Ad-Hoc Consensus Committee ancer treatment continues to become more diverse Abstract: Estrogen receptor (ER) status in breast cancer is Cand, at the same time, more personalized in recent currently the most important predictive biomarker that deter- years. This change is particularly true for breast cancer, mines breast cancer prognosis after treatment with endocrine where targeted therapy and hormonal therapy are the therapy. Although immunohistochemistry has been widely standard of care to suit the unique biologic tumor viewed as the gold standard methodology for ER testing in characteristics in each individual patient. It is now widely breast cancer, lack of standardized procedures, and lack of accepted that estrogen receptor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry

Loading next page...
 
/lp/wolters-kluwer-health/consensus-recommendations-on-estrogen-receptor-testing-in-breast-0QkvbR0u0T
ISSN
1541-2016
eISSN
1533-4058
DOI
10.1097/PAI.0b013e31818a9d3a
pmid
18931614
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry Hadi Yaziji, MD,* Clive R. Taylor, MA, MD, D.Phil,w Neal S. Goldstein, MD,z David J. Dabbs, MD,y Elizabeth H. Hammond, MD,J Bryan Hewlett, ART (CSMLS), MLT (CMLTO),z Alton D. Floyd, PhD,* Todd S. Barry, MD,# Alvn W. Martin, MD, ** Sunil Badve, MD, ww Frederick Baehner, MD, ww Richard W. Cartun, MD,zz Richard N. Eisen, MD,yy Paul E. Swanson, MD,JJ Stephen M. Hewitt, MD, PhD,zz Mogen Vyberg, MD,## and David G. Hicks, MD*** and Members of the Standardization Ad-Hoc Consensus Committee ancer treatment continues to become more diverse Abstract: Estrogen receptor (ER) status in breast cancer is Cand, at the same time, more personalized in recent currently the most important predictive biomarker that deter- years. This change is particularly true for breast cancer, mines breast cancer prognosis after treatment with endocrine where targeted therapy and hormonal therapy are the therapy. Although immunohistochemistry has been widely standard of care to suit the unique biologic tumor viewed as the gold standard methodology for ER testing in characteristics in each individual patient. It is now widely breast cancer, lack of standardized procedures, and lack of accepted that estrogen receptor

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Dec 1, 2008

There are no references for this article.